8-K/A: NVE Corp Extends Abbott Supply Deal, Boosts Pricing
Contract Amendment Disclosure
NVE Corporation has extended its key supplier partnering agreement with Abbott Laboratories through 2027, securing increased product pricing for 2026 and 2027.
Summary
- Amendment No. 12 to the Supplier Partnering Agreement between NVE Corporation (Seller) and Pacesetter, Inc., a subsidiary of Abbott Laboratories (Buyer), has been executed.
- The agreement's term has been extended through December 31, 2027, from its previous end date.
- Pricing for products supplied by NVE to Abbott Laboratories will increase for both 2026 and 2027.
- The Amendment No. 12 is effective as of January 1, 2026.
- The original Supplier Partnering Agreement was dated January 1, 2006, and has undergone multiple amendments over the years.
Sentiment
Score: 8
Explanation: The extension of a significant supplier agreement with a major customer like Abbott Laboratories, coupled with increased pricing, is a strong positive for NVE Corporation. It indicates continued demand for its specialized products, enhances revenue visibility, and strengthens a key strategic relationship, de-risking future revenue streams.
Positives
- Secured a multi-year extension of a significant supplier agreement with a major customer, Abbott Laboratories, through December 31, 2027.
- Achieved increased pricing for products supplied in 2026 and 2027, which is expected to positively impact revenue.
- Maintained a long-standing strategic partnership with a key player in the medical device industry, indicating continued demand for NVE's specialized products.
Negatives
- Specific details regarding the increased pricing for 2026 and 2027 were redacted, preventing a precise quantitative assessment of the financial impact.
- The parties have agreed to work on stabilizing costs and aligning pricing beyond 2027, suggesting potential future negotiations or cost pressures.
Future Outlook
The Supplier Partnering Agreement with Abbott Laboratories has been extended through December 31, 2027. Both parties have agreed to collaborate on stabilizing costs and aligning pricing for the period beyond 2027.
Management Comments
- Daniel A. Baker, President & Chief Executive Officer of NVE Corporation, signed Amendment No. 12 on December 10, 2025.
- Jonathan Harrington, DVP Operations+Supply Chain of Pacesetter, Inc. (a subsidiary of Abbott Laboratories), signed Amendment No. 12 on December 12, 2025.
Industry Context
NVE Corporation's continued and extended partnership with Abbott Laboratories, a leading global medical device company, underscores the critical role of NVE's specialized products (likely advanced sensors or components) within the high-growth medical technology sector. This agreement reinforces NVE's position as a key supplier in an industry demanding high reliability and innovation.
Stakeholder Impact
- Shareholders: Likely positive impact due to secured revenue stream, increased pricing, and strengthened relationship with a major customer, contributing to business stability and potential for future growth.
- Employees: Enhanced job security and stability resulting from the extension of a significant long-term contract.
- Customers (Abbott Laboratories): Ensures continued supply of critical components from a trusted partner, supporting their product manufacturing and supply chain stability.
Next Steps
- Continue supplying products to Abbott Laboratories under the terms of the amended agreement.
- Engage with Abbott Laboratories to stabilize costs and align pricing for the period beyond December 31, 2027.
Key Dates
| Date | Description |
|---|---|
| January 1, 2006 | Effective date of the original Supplier Partnering Agreement between Pacesetter, Inc. and NVE Corporation. |
| September 6, 2007 | Effective date of Amendment No. 1 to the Supplier Partnering Agreement. |
| December 15, 2009 | Effective date of Amendment No. 2 to the Supplier Partnering Agreement. |
| September 13, 2010 | Effective date of Amendment No. 3 to the Supplier Partnering Agreement. |
| February 1, 2011 | Effective date of Amendment No. 4 to the Supplier Partnering Agreement. |
| April 20, 2016 | Effective date of Amendment No. 5 to the Supplier Partnering Agreement. |
| December 16, 2020 | Effective date of Amendment No. 6 to the Supplier Partnering Agreement. |
| April 12, 2021 | Effective date of Amendment No. 7 to the Supplier Partnering Agreement. |
| November 10, 2021 | Effective date of Amendment No. 8 to the Supplier Partnering Agreement. |
| December 5, 2022 | Effective date of Amendment No. 9 to the Supplier Partnering Agreement. |
| December 5, 2023 | Effective date of Amendment No. 10 to the Supplier Partnering Agreement. |
| December 17, 2024 | Effective date of Amendment No. 11 to the Supplier Partnering Agreement. |
| December 10, 2025 | Date Amendment No. 12 was signed by NVE Corporation's President & CEO. |
| December 12, 2025 | Date Amendment No. 12 was signed by Pacesetter, Inc.'s DVP Operations+Supply Chain. |
| December 17, 2025 | Date the Form 8-K/A was signed and filed by NVE Corporation. |
| January 1, 2026 | Effective date of Amendment No. 12 to the Supplier Partnering Agreement. |
| December 31, 2027 | New termination date for the Supplier Partnering Agreement. |
Recommendation
buyThe extension of a significant supplier agreement with Abbott Laboratories through 2027, coupled with increased pricing for 2026 and 2027, provides NVE Corporation with enhanced revenue visibility and strengthens its long-term relationship with a critical customer in the medical device sector. This positive development de-risks future revenue streams and indicates strong demand for NVE's specialized products, making it an attractive investment opportunity.
Keywords
NVE Corporation, Abbott Laboratories, Pacesetter, Supplier Agreement, Contract Extension, Pricing Increase, Medical Devices, Semiconductor, Sensors
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.